Within this context, recently developed therapeutic agents such as sodium-glucose co-transporter-2 inhibitors and glucagone like peptide-1 receptor agonist have shown promising therapeutic potential not only to reduce CV risk but also to slow the progression of kidney disease with beneficial effect on albuminuria as well as on GFR [52–55]. This evidence concerns the gene GLP1R and kidney disorder.